ATS Blue Journal

Posting content from the American Journal of Respiratory and Critical Care Medicine; follows do not indicate endorsement.
#pulmCC #sleepmed #AJRCCM #RespEd #ATS

[ATS Blue Journal @ATSBlueEditor]

📣AJRCCM Call for Papers on Critical Care

The March 2027 issue of AJRCCM will feature a special section devoted to critical care. Submit your manuscript by October 31, 2026.

@ATSCritCare
@atscommunity

[American Thoracic Society (ATS) @atscommunity]

A new ATS clinical practice guideline addresses childhood interstitial lung disease (chILD) in infants. Published in this month’s issue of @ATSBlueEditor, the guideline provides evidence-based recommendations for the diagnosis and management of chILD in children younger than two years.

Access the full guideline now: https://t.co/WQItW7dhoY?

[ATS Blue Journal @ATSBlueEditor]

🎧 Revisit this episode from the Out of the Blue archives

The Effectiveness of Isoniazid Preventive Treatment Among Contacts of Multidrug-Resistant Tuberculosis: A Systematic Review and Individual-Participant Meta-Analysis
https://t.co/b79TWD2VAS
@atscommunity

[ATS Blue Journal @ATSBlueEditor]

ATS Blue Journal Editor's Choice: Residual disease activity in cystic fibrosis lung disease: implications for clinical management and research #CF @atscommunity https://t.co/vXJm4Al8c1

[ATS Blue Journal @ATSBlueEditor]

Granulomatous lymphocytic interstitial lung disease in common variable immunodeficiency-like disorder @atscommunity
https://t.co/uWNZ3soDcn

[ATS Blue Journal @ATSBlueEditor]

ATS Blue Journal Editor's Choice: Mycophenolate and azathioprine in fibrotic interstitial lung disease #ILD @atscommunity
https://t.co/yfpsGlIZN1

[ATS Blue Journal @ATSBlueEditor]

Three versus six weeks of corticosteroids for mild immune-related pneumonitis: a randomized trial @atscommunity
https://t.co/JSVa0Jza4X

[ATS Blue Journal @ATSBlueEditor]

Performance of age-adjusted whole genome sequencing telomere length in idiopathic pulmonary fibrosis #IPF @atscommunity
https://t.co/8ty2xXmOq7

[ATS Blue Journal @ATSBlueEditor]

Association of a polygenic risk score with diagnosis and outcomes in idiopathic pulmonary fibrosis #PF @atscommunity
https://t.co/3kad2aOCCy

[ATS Blue Journal @ATSBlueEditor]

Meaningful thresholds for change in quantitative computed tomography-derived fibrosis extent in idiopathic pulmonary fibrosis #IPF @atscommunity
https://t.co/Hulz9J7lcL

[ATS Blue Journal @ATSBlueEditor]

🎧 Revisit this episode from the Out of the Blue archives

“Social Apnea”: Obstructive Sleep Apnea Is Exacerbated on Weekends
https://t.co/XOZcfZWexA

@atscommunity
@ATSSRN

[ATS Blue Journal @ATSBlueEditor]

Gut microbiota associate with disease severity and survival in idiopathic pulmonary fibrosis #IPF @atscommunity https://t.co/MqilO16D9V

[ATS Blue Journal @ATSBlueEditor]

Association of a polygenic risk score with diagnosis and outcomes in idiopathic pulmonary fibrosis #IPF #AJRCCM @atscommunity
https://t.co/3kad2aOCCy

[ATS Blue Journal @ATSBlueEditor]

Identification of a conserved sequence of disease progression in idiopathic pulmonary fibrosis #AJRCCM #IPF @atscommunity
https://t.co/pOpDXSyT1d

[ATS Blue Journal @ATSBlueEditor]

MMP12 induces fibrogenic macrophage differentiation to drive granuloma-associated cardiac fibrosis
#ARJCCM @atscommunity
https://t.co/nbYdx1FifY

[ATS Blue Journal @ATSBlueEditor]

ADAMTS14 is a novel modulator of fibroblast mechanoactivation in pulmonary fibrosis
https://t.co/scexvSrCfY @atscommunity

[ATS Blue Journal @ATSBlueEditor]

The American Journal of Respiratory and Critical Care Medicine thanks all the authors in this issue for submitting their stellar work to the Blue Journal. The editors would like to highlight 17 emerging investigators who worked on articles in this issue. 
https://t.co/PTQdkpsx5w

[ATS Blue Journal @ATSBlueEditor]

International Working Group Report: Acute exacerbation in fibrotic interstitial lung disease #ILD
https://t.co/W8ChUOEHXY @atscommunity

[ATS Blue Journal @ATSBlueEditor]

Editorial: From mechanisms to clinical practice: introduction to an AJRCCM special section on interstitial lung disease #ILD
https://t.co/s6fEJ8CwT8 @atscommunity

[ATS Blue Journal @ATSBlueEditor]

Editorial: Cystic fibrosis in 2026: game over, or game on? Introduction to an AJRCCM special section on cystic fibrosis #CF https://t.co/Mf1Zns528S @atscommunity

[ATS Blue Journal @ATSBlueEditor]

🚨The October edition of the Blue Journal #AJRCCM is now available with special sections on Interstitial Lung Disease and Cystic Fibrosis. #ILD #CF https://t.co/39nPRMucoy @atscommunity